• Explore /
  • Videos & Slides
  • / CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors.

CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors.

Abstract Video & Slides Poster

Presenter

null

Meghan Mooradian, MD

Massachusetts General Hospital Cancer Center

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT02097225

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3609)

DOI

10.1200/JCO.2020.38.15_suppl.3609

Abstract #

3609

Poster Bd #

339

Abstract Disclosures

Similar Videos & Slides

Videos & Slides

2019 ASCO Annual Meeting

Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.

Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.

Speaker: Tae Won Kim, MD

Speaker: Michael A. Davies, MD, PhD

Speaker: Manisha H. Shah, MD

Speaker: Daruka Mahadevan, MD, PhD